Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Omicron BA.2.12.1, BA.4, and BA.5 subvariants evolved to extend antibody evasion
David D. Ho, Qian Wang, Yicheng Guo, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 12

Showing 12 citing articles:

Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
Projecting Omicron scenarios in the US while tracking population-level immunity
Anass Bouchnita, Kaiming Bi, Spencer J. Fox, et al.
Epidemics (2024) Vol. 46, pp. 100746-100746
Open Access | Times Cited: 6
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants
J. Andrew Duty, Thomas Kraus, Heyue Zhou, et al.
Med (2022) Vol. 3, Iss. 10, pp. 705-721.e11
Open Access | Times Cited: 16
Predicting COVID-19 disease severity from SARS-CoV-2 spike protein sequence by mixed effects machine learning
Bahrad A. Sokhansanj, Gail Rosen
Computers in Biology and Medicine (2022) Vol. 149, pp. 105969-105969
Open Access | Times Cited: 14
Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
Xiaohua Hao, Zheng Zhang, Ji Ma, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
Moving targets: COVID-19 vaccine efficacy against Omicron subvariants
Maria Karolaynne da Silva, U. L. Fulco, Edilson Dantas da Silva, et al.
Molecular Therapy (2022) Vol. 30, Iss. 8, pp. 2644-2645
Open Access | Times Cited: 9
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
Daryl Geers, Roos S. G. Sablerolles, Debbie van Baarle, et al.
iScience (2022) Vol. 26, Iss. 1, pp. 105753-105753
Open Access | Times Cited: 7
A global blockchain for recording high rates of COVID-19 vaccinations
Jorge Medina, Roberto Rojas‐Cessa, Ziqian Dong, et al.
Computers in Biology and Medicine (2023) Vol. 163, pp. 107074-107074
Open Access | Times Cited: 1
Projecting Omicron scenarios in the US while tracking population-level immunity
Anass Bouchnita, Kaiming Bi, Spencer J. Fox, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia
Christopher Radcliffe, Maricar Malinis, Marwan M. Azar
Clinics in Chest Medicine (2022) Vol. 44, Iss. 2, pp. 279-297
Open Access | Times Cited: 2
Covariance predicts conserved protein residue interactions important for the emergence and continued evolution of SARS-CoV-2 as a human pathogen
William P. Robins, John J. Mekalanos
PLoS ONE (2022) Vol. 17, Iss. 7, pp. e0270276-e0270276
Open Access | Times Cited: 1
Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial
Shabir A. Madhi, Gaurav Kwatra, Richard Welch, et al.
SSRN Electronic Journal (2022)
Closed Access
Page 1

Scroll to top